N. Saba et al., High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant, BONE MAR TR, 24(8), 1999, pp. 853-855
Citations number
14
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Dose-intensive chemotherapy with PBSC support was recently reported to be f
easible in cardiac amyloidosis with some patients achieving post-transplant
improvement in performance status. At our center, 11 patients with symptom
atic primary systemic amyloidosis and predominant cardiac involvement confi
rmed by biopsy or increased wall thickness on echocardiogram were evaluated
for high-dose therapy, The average time from diagnosis to referral was 11
months (4-26 months). Of the 11 patients, two were not candidates for high-
dose therapy, based on poor performance status. The remaining nine patients
proceeded to PBSC collection. Three patients died during the mobilization
period: two of rapid atrial fibrillation, and the third secondary to progre
ssive heart failure. Six patients proceeded to transplantation. However, on
e died of sudden cardiac arrest the day of melphalan administration, one fo
llowing hypotension related to stem cell infusion, and one of hypotensive s
hock the day following stem cell infusion. Three patients recovered and lef
t the hospital, but one died of a cardiorespiratory event at home within 6
weeks of discharge. Both surviving patients demonstrate objective improveme
nt. A decision to use high-dose therapy and stem cell support in cardiac am
yloidosis must balance the substantial morbidity of the procedure with the
potential benefits. Transplant regimens should avoid cardiotoxic agents suc
h as cyclophosphamide and DMSO and patients should receive anti-arrythmic t
herapy.